CL2011002631A1 - Formulacion farmaceutica liquida que comprende una sal de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina (vortioxetina) seleccionada entre la sal de adicion de acido dl-lactico, l-lactico y d-lactico; uso de la sal para el tratamiento de trastorno depresivo mayor y ansiedad generalizada, entre otras; y formas cristalinas del compuesto. - Google Patents

Formulacion farmaceutica liquida que comprende una sal de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina (vortioxetina) seleccionada entre la sal de adicion de acido dl-lactico, l-lactico y d-lactico; uso de la sal para el tratamiento de trastorno depresivo mayor y ansiedad generalizada, entre otras; y formas cristalinas del compuesto.

Info

Publication number
CL2011002631A1
CL2011002631A1 CL2011002631A CL2011002631A CL2011002631A1 CL 2011002631 A1 CL2011002631 A1 CL 2011002631A1 CL 2011002631 A CL2011002631 A CL 2011002631A CL 2011002631 A CL2011002631 A CL 2011002631A CL 2011002631 A1 CL2011002631 A1 CL 2011002631A1
Authority
CL
Chile
Prior art keywords
salt
lactic
dimethylphenylsulfanyl
vortioxetine
piperazine
Prior art date
Application number
CL2011002631A
Other languages
English (en)
Inventor
Svend Treppendahl
De Diego Heidi Lopez
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2011002631A1 publication Critical patent/CL2011002631A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
CL2011002631A 2009-04-24 2011-10-21 Formulacion farmaceutica liquida que comprende una sal de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina (vortioxetina) seleccionada entre la sal de adicion de acido dl-lactico, l-lactico y d-lactico; uso de la sal para el tratamiento de trastorno depresivo mayor y ansiedad generalizada, entre otras; y formas cristalinas del compuesto. CL2011002631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900531 2009-04-24

Publications (1)

Publication Number Publication Date
CL2011002631A1 true CL2011002631A1 (es) 2012-04-09

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002631A CL2011002631A1 (es) 2009-04-24 2011-10-21 Formulacion farmaceutica liquida que comprende una sal de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina (vortioxetina) seleccionada entre la sal de adicion de acido dl-lactico, l-lactico y d-lactico; uso de la sal para el tratamiento de trastorno depresivo mayor y ansiedad generalizada, entre otras; y formas cristalinas del compuesto.

Country Status (35)

Country Link
US (4) US8940746B2 (es)
EP (1) EP2421534B1 (es)
JP (1) JP5722879B2 (es)
KR (1) KR101779214B1 (es)
CN (2) CN104693145A (es)
AR (2) AR076400A1 (es)
AU (1) AU2010238946B2 (es)
BR (1) BRPI1015338C1 (es)
CA (1) CA2759456C (es)
CL (1) CL2011002631A1 (es)
CO (1) CO6450649A2 (es)
CR (1) CR20110554A (es)
DK (1) DK2421534T3 (es)
DO (2) DOP2011000319A (es)
EA (1) EA021122B1 (es)
ES (1) ES2512719T3 (es)
GE (1) GEP20135938B (es)
HK (1) HK1206732A1 (es)
HR (1) HRP20140880T1 (es)
IL (1) IL215362A0 (es)
MA (1) MA33298B1 (es)
MX (1) MX2011011119A (es)
MY (1) MY155288A (es)
NZ (1) NZ596431A (es)
PL (1) PL2421534T3 (es)
PT (1) PT2421534E (es)
RS (1) RS53539B1 (es)
SG (1) SG175124A1 (es)
SI (1) SI2421534T1 (es)
SM (1) SMT201400159B (es)
TN (1) TN2011000504A1 (es)
TW (1) TWI461224B (es)
UA (1) UA106985C2 (es)
WO (1) WO2010121621A1 (es)
ZA (1) ZA201107731B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20135938B (en) 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine
BR112015006075B1 (pt) 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
AU2014286308B2 (en) 2013-07-01 2018-05-10 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
US10562872B2 (en) 2016-02-08 2020-02-18 H. Lundbeck A/S Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN109310691A (zh) 2016-07-01 2019-02-05 H.隆德贝克有限公司 用于快速开始抗抑郁作用的给药方案
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE602004016316D1 (de) 2003-04-04 2008-10-16 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
ES2379200T5 (es) * 2006-06-16 2021-10-20 H Lundbeck As Bromhidrato de 1-[2-(2,4-Dimetilfenilsulfanil)fenil]piperazina como compuesto con recaptación de serotonina combinada con actividad 5-HT3 y 5-HT1A para el tratamiento del deterioro cognitivo
EP2044020B1 (en) 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
GEP20135938B (en) 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
UA106985C2 (uk) 2014-11-10
RS53539B1 (en) 2015-02-27
HK1206732A1 (en) 2016-01-15
CA2759456C (en) 2017-10-31
US20170224677A1 (en) 2017-08-10
SG175124A1 (en) 2011-12-29
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
BRPI1015338C1 (pt) 2021-08-10
AU2010238946B2 (en) 2013-03-28
EA021122B1 (ru) 2015-04-30
MY155288A (en) 2015-09-30
MX2011011119A (es) 2011-11-04
KR101779214B1 (ko) 2017-09-18
BRPI1015338B8 (pt) 2021-05-25
TWI461224B (zh) 2014-11-21
IL215362A0 (en) 2011-12-29
KR20120022809A (ko) 2012-03-12
AR122051A2 (es) 2022-08-10
US10857149B2 (en) 2020-12-08
SI2421534T1 (sl) 2014-11-28
CN104693145A (zh) 2015-06-10
BRPI1015338B1 (pt) 2021-01-05
DOP2011000319A (es) 2012-02-29
ZA201107731B (en) 2013-02-27
DOP2012000211A (es) 2013-03-31
CA2759456A1 (en) 2010-10-28
NZ596431A (en) 2012-12-21
PT2421534E (pt) 2014-10-29
EA201171287A1 (ru) 2012-04-30
JP5722879B2 (ja) 2015-05-27
MA33298B1 (fr) 2012-05-02
SMT201400159B (it) 2015-01-15
EP2421534A1 (en) 2012-02-29
US8940746B2 (en) 2015-01-27
DK2421534T3 (da) 2014-10-13
US10034876B2 (en) 2018-07-31
CN102405048A (zh) 2012-04-04
TN2011000504A1 (en) 2013-05-24
GEP20135938B (en) 2013-10-10
PL2421534T3 (pl) 2014-12-31
HRP20140880T1 (hr) 2014-11-07
TW201041604A (en) 2010-12-01
US20150094316A1 (en) 2015-04-02
ES2512719T3 (es) 2014-10-24
US20120035188A1 (en) 2012-02-09
US20190167667A1 (en) 2019-06-06
US9475748B2 (en) 2016-10-25
WO2010121621A1 (en) 2010-10-28
JP2012524735A (ja) 2012-10-18
AU2010238946A1 (en) 2011-12-08
CO6450649A2 (es) 2012-05-31
AR076400A1 (es) 2011-06-08
BRPI1015338A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
CL2011002631A1 (es) Formulacion farmaceutica liquida que comprende una sal de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina (vortioxetina) seleccionada entre la sal de adicion de acido dl-lactico, l-lactico y d-lactico; uso de la sal para el tratamiento de trastorno depresivo mayor y ansiedad generalizada, entre otras; y formas cristalinas del compuesto.
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
PE20150998A1 (es) Inhibidores de histona demetilasas
CL2015003442A1 (es) Derivados heterociclicos
CL2014002087A1 (es) Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal.
CU24053B1 (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
BR112014022214A2 (pt) fenólicos antibacterianos
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
CU20130126A7 (es) Inhibidores sustituidos de acetil-coa carboxilasa
AR067328A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
CL2018000057A1 (es) Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares
CL2014000149A1 (es) Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
CL2014002306A1 (es) Una composicion farmaceutica intravenosa que comprende al compuesto acido {8-fluoro-2-[4-(3-metoxifenil)-piperazina-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolina-4-il}acetico, al menos un excipiente seleccionado de ciclodextrinas, lisina y arginina, y agua; su metodo de preparacion; y su uso para el tratamiento y/o profilaxis de infecciones por virus.
ECSP11011503A (es) Compuestos carboxamida y su uso como inhibidores de calpaína.
CL2007003042A1 (es) Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte
BR112013002651A2 (pt) forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesma
PE20142337A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
AR128158A2 (es) Compuesto heterocíclico
CL2013000929A1 (es) Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt.
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
AR093188A1 (es) Sal y uso medico